These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 28515094)

  • 1. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
    Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
    Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
    Power J; Poole KE; van Bezooijen R; Doube M; Caballero-Alías AM; Lowik C; Papapoulos S; Reeve J; Loveridge N
    J Bone Miner Res; 2010 Aug; 25(8):1867-76. PubMed ID: 20200987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
    Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
    Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model.
    Morse A; McDonald MM; Schindeler A; Peacock L; Mikulec K; Cheng TL; Liu M; Ke HZ; Little DG
    Calcif Tissue Int; 2017 Aug; 101(2):217-228. PubMed ID: 28391431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.
    Hadaya D; Gkouveris I; Soundia A; Bezouglaia O; Boyce RW; Stolina M; Dwyer D; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2019 Jan; 34(1):171-181. PubMed ID: 30184271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.